









С



d

b



е



f







С



d



е



f



а





С



d







С



а

| MEF p100 -/- | |
|--------------|--------------------|
| 0H 6H 16H | Tweak+TNF α |
| | Cleav. |
| | Casp-8 |
| | Cleav. |
| | Casp-3 |



aly/wt









aly/aly

d

С



Figure S1: NIK-deficient cells resist to Tweak/TNFα-induced cell death

(a) Two independent clones of NIK WT and NIK KO MEFs were treated for 24 hours with Tweak (200 ng/ml) and TNFα (200 U/ml) and cell survival was measured with Cell Titer-Glo kit. (b) *aly/aly* homozygote MEFs were treated and analyzed like in (a).

Figure S2: NIK/RIP1-mediated caspase activation acts through the mitochondrial pathway

(a) RIP1 ^{+/+} and RIP1 ^{-/-} MEFs were treated for 24 hours with or without TNF α (200 U/ml) and increasing amount of the Smac mimetics CmpA (250 nM), and cell survival was measured with Cell Titer-Glo kit. (b) NIK ^{+/+} and NIK ^{-/-} MEFs were treated as indicated and protein extracts were analyzed by Western-blot for phosphor-JNK expression. (c) Independent WT and KO MEFs for NIK were tested for their expression level of c-FLIP by Western-blot. (d) NIK KO MEFs reconstituted with empty vector (EV), NIK WT (WT) or NIK kinase-dead (KD) were analyzed for their c-FLIP content (c) DEVDase activity of Bax/Bak ^{+/+} and Bax/Bak ^{-/-} MEFs treated for various time with two doses of Tweak and a fixed concentration of TNF α (200 U/ml) and TNF α (200 U/ml) for different time periods. Levels of cleaved caspase-8 and cleaved caspase-3 were assessed by Western-blot. Statistical analyses: *** P<0.001.

Figure S3: RIP1 is a substrate of NIK but its interaction does not require the RHIM domain

(a) HEK293T cells were transfected with GFP-RIP3 and FL kinase dead RIP1-V5 or Δ RHIM RIP1-V5 expression vectors. RIP3-GFP complexes were immunoprecipitated using an anti-GFP antibody and RIP1 interactions were revealed by Western-blot with an anti-RIP1 antibody. (b) Specificity of recombinant full-length RIP1was assessed by *in vitro* kinase assay using RIP1 kinase inhibitor Nec-1. (c) Specificity of recombinant NIK kinase domain was assessed by *in vitro* kinase assay using NIK kinase inhibitor Nec-1. (d) NIK ^{+/+} and NIK ^{-/-} MEFs were left untreated or treated with a mix of TNF α and Smac mimetics (CmpA) and the phosphorylation status of RIP1 was analyzed by Western-blot with cell extracts treated or not with lambda phosphatase (λ phos.). (e) *In vitro* kinase assay with active full-length RIP1 in the presence of active recombinant NIK and the RIP1 kinase inhibitor Nec-1. (f) *In vitro* kinase assay with inactive full-length RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK and the RIP1 in the presence of active recombinant NIK.

Figure S4: Smac mimetics/TNF α -induced complex IIb assembly is defective in NIKdeficient MEFs

(a) NIK ^{+/+} and NIK ^{-/-} MEFs were treated with CmpA and/or TNF α for the indicated time periods prior to an immunoprecipitation with an anti-caspase-8 antibody and detection of both caspase-8 and RIP1 by Western-blot. (b) Expression profile of death domain-containing proteins in NIK +/+ and NIK -/- MEFs treated with Tweak/TNF α in the presence of z-VAD-FMK (TTZ). (c) Level of c-IAP1/2 depletion in NIK ^{+/+} and NIK ^{-/-} MEFs treated with CmpA, ns, non-specific signal. (d) NIK ^{+/+} MEFs were treated with Tweak/TNF α /Z-VAD for 60 min. prior to immunoprecipitation with irrelevant or anti-NIK antibodies. The immunoprecipitates were subjected to *in vitro* caspase-8 activity measurement. P value was 0,02.

Figure S5: TNFR1/LTβR-induced thymus involution and cell death is blocked in NIK knock-out mice.

(a) Images of thymi from postnatal (8 weeks) BM reconstitution experiments. Lethally irradiated (1100 rad) WT and NIK ^{-/-} recipient mice were reconstituted with BM from Tg Lck-LT $\alpha\beta$ mice. (b) Quantitative analyses of relative thymus weight of reconstitution experiments achieved in (a). (c) Analysis of thymic architecture (H&E staining) of the indicated post-reconstitution (5-6 weeks) experiments and cleaved caspase-3 staining. Statistical analyses: *** P<0.001.

Figure S6: p100-deficiency does not prevent Tweak/TNFα-induced apoptosis.

MEFs deficient for p100 treated with Tweak and TNF α displays the apoptotic cleavage of caspase-8 and caspase-3.

Figure S7: RIP1 and NIK mediate Adenoviral/TNF α -induced hepatocyte caspase-3 cleavage.

(**a**, **b**) Dosage of serum ALT and serum AST in *aly*/wt (n=3) and *aly* / *aly* (n=3) mice treated for 4 hours with D-Gal-N and TNF α . (**c**, **d**) Dosage of serum ALT and serum AST in WT mice treated for 4 hours with D-Gal-N and TNF α in the presence or absence of Nec-1 (n=3 for each treatment).